- Home
- DOX vs CDTX Comparison
DOX vs CDTX Comparison
Compare DOX & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOX | CDTX |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.0B |
| IPO Year | 1998 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DOX | CDTX |
|---|---|---|
| Price | $82.64 | $221.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $97.00 | ★ $128.75 |
| AVG Volume (30 Days) | 993.1K | ★ 1.0M |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | ★ 19.01 | N/A |
| EPS | ★ 5.05 | N/A |
| Revenue | ★ $4,532,913,000.00 | N/A |
| Revenue This Year | $4.57 | N/A |
| Revenue Next Year | $4.11 | N/A |
| P/E Ratio | $16.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $74.32 | $15.22 |
| 52 Week High | $95.41 | $221.42 |
Technical Indicators
Market Signals| Indicator | DOX | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.74 | 84.92 |
| Support Level | $79.45 | $220.47 |
| Resistance Level | $82.04 | $221.42 |
| Average True Range (ATR) | 1.34 | 0.41 |
| MACD | 0.24 | -2.93 |
| Stochastic Oscillator | 94.72 | 97.68 |
Price Performance
Historical ComparisonAbout DOX Amdocs Limited
Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.